Mission
The Parkinson’s Disease Foundation (PDF) is a leading national presence in Parkinson’s disease research, education and public advocacy
On April 29, 2016, pimavanserin (Nuplazid™) was approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The approval was announced by the drug's manufacturer, Acadia Pharmaceuticals Inc. What does it mean for people with Parkinson's disease?
Where your support goes
We are working for the nearly one million people in the US who live with Parkinson’s by funding promising scientific research while supporting people living with Parkinson’s through educational programs and services.
The results
1957, PDF has dedicated more than $115 million to fund the work of leading scientists throughout the world and nearly $50 million to support national education and advocacy initiatives.
RELATED ORGANIZATIONS
